Publication date: Jun 08, 2019
STRIVE is a multicenter, observational, open-label, single-arm study of natalizumab in anti-JC virus (JCV) seronegative patients with early relapsing-remitting multiple sclerosis (RRMS). The objective of this prespecified 2-year interim analysis was to determine the effectiveness of natalizumab in establishing and maintaining no evidence of disease activity (NEDA) in early RRMS.
Patients aged 18-65 years had an RRMS diagnosis
Open Access PDF
Perumal, J., Fox, R.J., Balabanov, R., Balcer, L.J., Galetta, S., Makh, S., Santra, S., Hotermans, C., and Lee, L. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE. 18276. 2019 BMC Neurol (19):1.
- Real-world study of efficacy, risk management and reasons for discontinuation of natalizumab for treatment of multiple sclerosis in Russia.